Table 1.
Clinical trials of CD8+ T cell-based cancer immunotherapy
| Types of Immunotherapy |
Target | Drugs/Biologics | Types of cancer (s) | NCT number |
|---|---|---|---|---|
| Immune checkpoint blocker therapy | Anti-PD 1/PD-L1 | Nivolumab (Opdivo) | Glioblastoma | NCT02550249, NCT03430791, NCT02529072 |
| Pembrolizumab | Hodgkin Lymphoma | NCT02453594, NCT02875067 | ||
| Tislelizumab (BGB-A317) | Lung Cancer | NCT03745222, NCT04005716 | ||
| Cemiplimab (REGN2810) | Non-Small Cell Lung Cancer | NCT03367819, NCT03515629 | ||
| Avelumab | Gastric Cancer | NCT02625623, NCT02625610 | ||
| Durvalumab | Squamous Cell Carcinoma | NCT03144738, NCT02262741 | ||
| Atezolizumab | Cutaneous Melanoma | NCT04020809 | ||
| Colorectal Carcinoma | NCT02788279 | |||
| Bladder Cancer | NCT03359239, NCT02951767 | |||
| Metastatic Pancreatic Cancer | NCT04820179 | |||
| Anti-CTLA-4 | Ipilimumab | Prostate Cancer | NCT02113657, NCT01804465, NCT00064129 | |
| Tremelimumab | Melanoma | NCT02535078, NCT00378482 | ||
| Cancer vaccine | Peptide vaccines | HER2/Neu Peptide Vaccine |
Breast Cancer Colorectal Cancer |
|
| Polypepi1018 CRC vaccine | Colorectal Carcinoma | NCT05130060 | ||
| MUC1-KLH vaccine | Prostate Cancer | NCT00005632 | ||
| Dendritic Cell vaccine | NY-ESO-1 peptide-pulsed autologous dendritic cell vaccine |
Solid Neoplasm Melanoma (Skin) |
||
| Autologous dendritic cell vaccine | Breast Cancer | NCT04879888, NCT00019084 | ||
|
Tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic |
Metastatic Breast Cancer | NCT02479230 | ||
| cell vaccine | ||||
| DNA vaccine | Mammaglobin-A DNA vaccine | Metastatic Breast Cancer | NCT00807781 | |
|
Personalized polyepitope DNA vaccine |
Triple Negative Breast Cancer | NCT02348320 | ||
| RNA vaccine | CV9103 | Hormonal Refractory Prostate Cancer | NCT00831467, NCT00906243 | |
| RBL001/RBL002 | Melanoma | NCT01684241 | ||
| Neoantigen vaccines | Personalized vaccine | Melanoma | NCT01970358, NCT03480152 | |
| NEO-PV-01 | Non-Small Cell Lung Cancer | NCT03380871 | ||
| Cell therapy | Adoptive Cell Transfer Therapy | Therapeutic autologous lymphocytes | Brain and Central Nervous System Tumors | NCT00730613, NCT00331526, NCT00003158 |
| Autologous cytokine-induced killer cells | Hepatocellular Carcinoma | NCT03124498 | ||
| CAR-T cells | Anti-meso CAR-T cells | Mesothelioma | NCT01355965, NCT02159716 | |
| Anti-CD19 CAR-T cells | Lymphoblastic Leukemia | NCT02975687, NCT03076437 | ||
| Anti-CEA CAR-T cells | Pancreatic Cancer | NCT02850536 | ||
| Anti-GPC3 CAR-T cells | Hepatocellular Carcinoma | NCT02395250 | ||
| Anti-CD19/22 CAR-T cells | Acute Lymphoblastic Leukemia | NCT05418088, NCT05674175 | ||
| Anti-BCMA CAR-T cells | Multiple Myeloma | NCT02658929, NCT03455972 | ||
| Anti-EGFRVIII CAR-T cells | Glioblastoma | NCT01454596 | ||
| Anti-GD2 CAR-T cells | Melanoma | NCT02107963 | ||
| Anti-CD133 CAR-T cells | Colorectal Cancer | NCT02541370 | ||
| TCR-T cells | Autologous WT1 TCR transduced T cells | Myeloid Leukemia | NCT02550535, NCT02770820 | |
| Non-Small Cell Lung Cancer | NCT02408016 | |||
| Anti-NY-ESO-1 engineered T cells | Soft-Tissue Sarcomas | NCT05296564 | ||
| Anti-P53 T-cell receptor transduced lymphocytes | Kidney Cancer | NCT00704938 | ||
| NYESO-1 T cells | Melanoma | NCT02062359, NCT00518206, NCT01967823 | ||
| Nanomedicine treatment | Nano drug | Magnetic nanoparticle | Prostate Cancer | NCT02033447, NCT00147238 |
| Carbon nanoparticles | Thyroid Cancer | NCT02724176, NCT06048367 | ||
| Docetaxel nanoparticles (BIND-014) |
Prostate Cancer Non-Small Cell Lung Cancer |
|||
| Nab-Paclitaxel (Abraxane) | Biliary Cancers | NCT02392637 | ||
| Ferumoxytol (Feraheme) | Bladder Cancer | NCT02141490 | ||
| BP-C1 | Pancreatic Cancer | NCT03627390 | ||
| Paclitaxel (Genexol®) | Breast Cancer | NCT00876486 |